Clinical trials: Radiation Oncology
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Head and Neck Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
The purpose of this study is to evaluate the efficacy, safety and tolerability of palifermin on the incidence of oral mucositis in subjects with locally advanced head and neck cancer receiving postoperative radiotherapy.
- Trial name
- NCT00540332
- Testing
- palifermin
- Sponsor
- Swedish Orphan Biovitrum
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Colorectal Cancer, Neoplasms
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
The purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
- Conditions
- Colorectal Cancer, Neoplasms, Intestinal Neoplasms, Digestive System Neoplasms
- Trial name
- NCT02202928
- Testing
- DC-CIK, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Anemia, Cancer
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
- Trial name
- NCT00083434
- Testing
- Epoetin alfa
- Where
- 6 sites in United States
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Leukemia, Lymphoma
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Open label palifermin will be administered to subjects who are at a risk of developing mucositis after radiotherapy and chemotherapy followed by blood stem cell support.
- Conditions
- Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00070616
- Testing
- Palifermin 6 x 60 μg/kg/day, Palifermin 2 x 180 μg/kg/day, radiotherapy
- Volunteers
- 25 people
- Sponsor
- Swedish Orphan Biovitrum
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.
- Trial name
- NCT01205321
- Testing
- Bombesin (68Ga) labeled (BAY86-7548)
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Lantheus Biosciences Ltd.
Tumor, Solid
Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou)
This study is prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 subjects enrolled.
- Trial name
- NCT06338436
- Testing
- Proton Radiation Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Melanoma
TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who have cancer which is not considered curable by surgery will receive intratumoral injections of TNFerade™ plus radiation as a 4-week…
- Trial name
- NCT00261404
- Testing
- TNFerade™
- Where
- United States
- Sponsor
- GenVec
Ototoxicity
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
The purpose of this study is to evaluate whether DB-020 administered via an injection in the middle ear prevents hearing loss in participants who will receive high doses of cisplatin as part of their treatment for cancer.
- Trial name
- NCT04262336
- Testing
- DB-020
- Where
- 8 sites in United States, Australia
- Volunteers
- 22 people
- Sponsor
- Decibel Therapeutics
Alopecia, Radiodermatitis
Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy
The study will evaluate the safety of topical norepinephrine in head and neck cancer patients who are receiving treatment with intensity modulated radiotherapy (IMRT).
- Trial name
- NCT01367990
- Testing
- Norepinephrine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ProCertus BioPharm, Inc
Over-Active Bladder
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
- Trial name
- NCT01777217
- Testing
- Solifenacin succinate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Advanced Research Network
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell…
- Trial name
- NCT06736418
- Testing
- 225Ac-ABD147
- Where
- 12 sites in United States
- Volunteers
- 17 people
- Sponsor
- Abdera Therapeutics Inc.
Glioblastoma
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT…
- Trial name
- GLORIA (NCT04121455)
- Testing
- Olaptesed pegol, Radiotherapy, Bevacizumab
- Where
- 6 sites in Germany
- Volunteers
- 117 people
- Sponsor
- TME Pharma AG
Endometrial Cancer
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2…
- Trial name
- NCT07022483
- Testing
- Trastuzumab Deruxtecan, Chemotherapy
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 710 people
- Sponsor
- Daiichi Sankyo
Prostatic Neoplasms
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
This is an uncontrolled, open-label, non-randomized Phase I study to investigate safety, biodistribution, radiation dosimetry and pharmacokinetics of a single dose of BAY88-8223 in Japanese patients with castration-resistant…
- Trial name
- NCT01565746
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Bayer
Squamous Cell Carcinoma, DaRT Treated Patients
A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT
Evaluation of long-term efficacy outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response.
- Trial name
- NCT05125354
- Where
- 2 sites in Israel, Italy
- Volunteers
- 33 people
- Sponsor
- Alpha Tau Medical LTD.
Metastatic Lesions in Vertebral Bodies
Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)
The purpose of this study is to evaluate treating painful metastatic lesions in vertebral bodies with pathologic fractures with targeted radiofrequency ablation (t-RFA) and vertebral augmentation (VA) prior to or following…
- Trial name
- STARRT (NCT02225223)
- Testing
- STAR™ Tumor Ablation System, StabiliT® Vertebral Augmentation System
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- Merit Medical Systems, Inc.
Hepatocellular Carcinoma (HCC)
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
- Trial name
- GPC3 (NCT06726161)
- Testing
- RYZ811, RYZ801
- Where
- 13 sites in United States
- Volunteers
- 590 people
- Sponsor
- RayzeBio, Inc.
Healthy Volunteers, Breast Cancer
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Primary purpose of the clinical study is to evaluate the safety, biodistribution and radiation dosimetry of [131I]-SGMIB Anti-HER2 VHH1 in healthy volunteers and patients with HER2+ breast cancer.
- Trial name
- CAM-VHH1 (NCT02683083)
- Testing
- [131I]-SGMIB Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Precirix